- Home
- REGN vs AMT Comparison
REGN vs AMT Comparison
Compare REGN & AMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REGN | AMT |
|---|---|---|
| Founded | 1988 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2B | 79.4B |
| IPO Year | 1995 | 1998 |
Fundamental Metrics
Financial Performance| Metric | REGN | AMT |
|---|---|---|
| Price | $612.14 | $187.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 16 |
| Target Price | ★ $830.16 | $222.38 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | 0.55% | ★ 4.02% |
| EPS Growth | 8.19 | ★ 12.03 |
| EPS | ★ 6.75 | 1.84 |
| Revenue | $5,872,227,000.00 | ★ $10,644,600,000.00 |
| Revenue This Year | $12.45 | $2.41 |
| Revenue Next Year | $10.13 | $3.42 |
| P/E Ratio | ★ $90.55 | $103.08 |
| Revenue Growth | ★ 20.82 | 5.11 |
| 52 Week Low | $503.25 | $165.08 |
| 52 Week High | $821.11 | $234.33 |
Technical Indicators
Market Signals| Indicator | REGN | AMT |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 54.09 |
| Support Level | $610.60 | $181.72 |
| Resistance Level | $618.01 | $196.49 |
| Average True Range (ATR) | 15.86 | 4.65 |
| MACD | 2.45 | 0.12 |
| Stochastic Oscillator | 39.95 | 44.35 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About AMT American Tower Corporation (REIT)
American Tower owns and operates about 150,000 wireless towers throughout the US, Asia, Latin America, Europe, and Africa. It also owns and/or operates 30 data centers in 11 US markets after acquiring CoreSite. The company's customer base in the tower business is very concentrated, with most revenue in each market generated by the top three or four mobile carriers. The company operates more than 40,000 towers in the US, which accounted for about half of total revenue in 2025. Outside the US, American Tower operates about 47,000 towers in Latin America (dominated by Brazil), 33,000 towers in Europe, and 28,000 towers in Africa. American Tower operates as a REIT.